David Porras1, Esther Nistal1,2, Susana Martínez-Flórez1, José Luis Olcoz2,3, Ramiro Jover3,4,5, Francisco Jorquera2,3, Javier González-Gallego1,3, María Victoria García-Mediavilla1,3, Sonia Sánchez-Campos1,3. 1. Institute of Biomedicine (IBIOMED), University of León, 24071, León, Spain. 2. Department of Gastroenterology. Complejo Asistencial Universitario de León, 24008, León, Spain. 3. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, 28029, Madrid, Spain. 4. Experimental Hepatology Unit, IIS Hospital La Fe, 46026, Valencia, Spain. 5. Department of Biochemistry and Molecular Biology, University of Valencia, 46010, Valencia, Spain.
Abstract
SCOPE: Modulation of intestinal microbiota has emerged as a new therapeutic approach for non-alcoholic fatty liver disease (NAFLD). Herein, it is addressed whether gut microbiota modulation by quercetin and intestinal microbiota transplantation can influence NAFLD development. METHODS AND RESULTS: Gut microbiota donor mice are selected according to their response to high-fat diet (HFD) and quercetin in terms of obesity and NAFLD-related biomarkers. Germ-free recipients displayed metabolic phenotypic differences derived from interactions between microbiota transplanted, diets, and quercetin. Based on the evaluation of hallmark characteristics of NAFLD, it is found that gut microbiota transplantation from the HFD-non-responder donor and the HFD-fed donor with the highest response to quercetin results in a protective phenotype against HFD-induced NAFLD, in a mechanism that involves gut-liver axis alteration blockage in these receivers. Gut microbiota from the HFD-responder donor predisposed transplanted germ-free mice to NAFLD. Divergent protective and deleterious metabolic phenotypes exhibited are related to definite microbial profiles in recipients, highlighting the predominant role of Akkermansia genus in the protection from obesity-associated NAFLD development. CONCLUSIONS: The results provide scientific support for the prebiotic capacity of quercetin and the transfer of established metabolic profiles through gut microbiota transplantation as a protective strategy against the development of obesity-related NAFLD.
SCOPE: Modulation of intestinal microbiota has emerged as a new therapeutic approach for non-alcoholic fatty liver disease (NAFLD). Herein, it is addressed whether gut microbiota modulation by quercetin and intestinal microbiota transplantation can influence NAFLD development. METHODS AND RESULTS: Gut microbiota donormice are selected according to their response to high-fat diet (HFD) and quercetin in terms of obesity and NAFLD-related biomarkers. Germ-free recipients displayed metabolic phenotypic differences derived from interactions between microbiota transplanted, diets, and quercetin. Based on the evaluation of hallmark characteristics of NAFLD, it is found that gut microbiota transplantation from the HFD-non-responder donor and the HFD-fed donor with the highest response to quercetin results in a protective phenotype against HFD-induced NAFLD, in a mechanism that involves gut-liver axis alteration blockage in these receivers. Gut microbiota from the HFD-responder donor predisposed transplanted germ-free mice to NAFLD. Divergent protective and deleterious metabolic phenotypes exhibited are related to definite microbial profiles in recipients, highlighting the predominant role of Akkermansia genus in the protection from obesity-associated NAFLD development. CONCLUSIONS: The results provide scientific support for the prebiotic capacity of quercetin and the transfer of established metabolic profiles through gut microbiota transplantation as a protective strategy against the development of obesity-related NAFLD.
Authors: Sara Carbajo-Pescador; David Porras; María Victoria García-Mediavilla; Susana Martínez-Flórez; María Juarez-Fernández; María José Cuevas; José Luis Mauriz; Javier González-Gallego; Esther Nistal; Sonia Sánchez-Campos Journal: Dis Model Mech Date: 2019-04-30 Impact factor: 5.758
Authors: Rocío Quiroga; Esther Nistal; Brisamar Estébanez; David Porras; María Juárez-Fernández; Susana Martínez-Flórez; María Victoria García-Mediavilla; José A de Paz; Javier González-Gallego; Sonia Sánchez-Campos; María J Cuevas Journal: Exp Mol Med Date: 2020-07-06 Impact factor: 8.718